Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 952 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07287982RecruitingPhase 2
ARGX-119 for children with SMA who can walk
This study tests a new medicine called ARGX-119 in children with SMA. It is given through an IV and aims to help kids who can already walk get stronger and stay healthy.
Little Rock, ArkansasAges 5–17 - NCT06884865RecruitingPhase 2
Study of an experimental knee injection for osteoarthritis pain
This study tests a new investigational medicine injected into the knee to see if it is safe and tolerable for people with painful knee osteoarthritis. It may help reduce pain and improve knee function.
Birmingham, AlabamaAges 45–80 - NCT04976322Enrolling by invitationPhase 3
Long-term lupus treatment safety study with dapirolizumab
This Phase 3 study tests whether dapirolizumab pegol is safe and tolerable for people with systemic lupus erythematosus (SLE) when taken long-term. You may be offered a chance to stay on this medicine if the study team thinks you could benefit.
Birmingham, AlabamaAges 16 years+ - NCT07156201RecruitingPhase 1
Safety study of oral ABS-1230 in healthy adults
This trial tests a new oral medication called ABS-1230 in healthy people to see how safe it is and how the body processes it. You would take either the drug or a placebo (no active ingredient) and be monitored closely.
Sydney, New South WalesAges 18–55 - NCT07498335RecruitingPhase 3
Atrasentan for children with IgA nephropathy
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
Neptune City, New JerseyAges 2–18 - NCT07235384RecruitingPhase 1
Zai Lab tests ZL-1503 for moderate to severe eczema
This study tests a new medication called ZL-1503 for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The trial will check if the drug is safe and how well it works.
Woolloongabba, QueenslandAges 18–65 - NCT07583251RecruitingPhase 1
Safety of a supplement for mild memory loss
This trial tests an oral supplement called gamma glutamylcysteine (GGC) in people with mild cognitive impairment (MCI) to see if it is safe and well-tolerated. It may help by supporting the body's natural defenses against cell damage.
Pittsburgh, PennsylvaniaAges 55–80 - NCT07600736RecruitingPhase 2
Safety study of ABS-1230 for children with KCNT1 epilepsy
This trial tests a new drug called ABS-1230 in children and young adults with KCNT1-related epilepsy, a rare genetic form of epilepsy. The study will check if the drug is safe and if it helps reduce seizures.
Hackensack, New JerseyAges 1 month–21 years - NCT07427394RecruitingPhase 2
Camizestrant and atirmociclib for advanced breast cancer
This trial tests two experimental drugs—camizestrant and atirmociclib—for women with advanced ER-positive breast cancer that has worsened after prior treatment. The goal is to see if the combination is safe and tolerable.
St Louis, MissouriAges 18 years+ - NCT07540897RecruitingPhase 3
Testing ALKS 2680 for narcolepsy type 1
This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.
Miami, FloridaAges 18–70 - NCT06976268RecruitingPhase 2/Phase 3
Testing BHV-8000 for early Parkinson's disease
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
Birmingham, AlabamaAges 40–80 - NCT06934967RecruitingPhase 3
Iptacopan study for children with PNH
This trial tests an oral medication, iptacopan, for children with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood condition. It aims to see how well the drug works in kids who have not tried anti-C5 therapy or who are switching from it.
Atlanta, GeorgiaAges 2–18 - NCT06615206Recruiting
First CRISPR RNA therapy for MECP2 duplication syndrome
This trial tests a new CRISPR therapy that edits RNA to treat a rare genetic condition called MECP2 duplication syndrome (MDS). It is for boys aged 2 to 18 who have stable seizures and no other major health problems, with the goal of improving symptoms and safety.
Beijing, Beijing MunicipalityAges 2–18 - NCT07747779Recruiting
Comparing two weight-loss surgeries for very high body weight
This study compares two types of weight-loss surgery to see how they affect hormones after a meal. It may help you choose a surgery that improves your health and weight loss.
Pathum Wan, BangkokAges 18–60 - NCT07005180RecruitingPhase 2
Carbon monoxide gas for Parkinson's disease
This trial tests if a low dose of carbon monoxide (HBI-002) is safe and helpful for people with Parkinson's disease. It requires specific health criteria and stable Parkinson's medication.
Fountain Valley, CaliforniaAges 40–80 - NCT07569029RecruitingPhase 1
HIV vaccine with treatment break to boost immune response
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
Birmingham, AlabamaAges 18–60 - NCT06821503RecruitingPhase 1/Phase 2
Study of LM-108 with chemo for advanced pancreatic cancer
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06840821RecruitingPhase 1/Phase 2
Testing MB0151 for cancers with somatostatin receptors
This trial tests a new drug, MB0151, for adults with advanced solid tumors that have somatostatin receptors and have not responded to standard treatments. It aims to see if MB0151 is safe and can shrink tumors.
Jinan, ShandongAges 18 years+ - NCT06736275RecruitingEarly Phase 1
Testing a new gene therapy for advanced solid tumors
This trial tests an experimental gene therapy called SXRN for people with advanced solid tumors that haven't responded to standard treatments. The study aims to see if it's safe and may help slow the disease.
BeijingAges 18–75 - NCT06794541RecruitingPhase 2
Testing eravacycline for kids with serious belly infections
This trial tests an antibiotic called eravacycline for children (ages 8–17) with serious belly infections. The medicine is given through an IV in the hospital to see if it is safe and tolerable.
Los Angeles, CaliforniaAges 8–17 - NCT06684964Recruiting
Real-world study of asciminib for chronic CML in Saudi Arabia
This study is watching how well asciminib (Scemblix) works in real life for people with chronic-phase CML in Saudi Arabia. If you've already tried two or more targeted therapies (TKIs) and recently started asciminib, this study may help doctors understand more about its effectiveness and side effects.
DammamAges 18–99 - NCT06677229RecruitingPhase 1/Phase 2
Safety and effectiveness of TZ-161 for spinal cord injury
This trial tests a new medicine called TZ-161 in people who have recently had a spinal cord injury in the chest area. The goal is to see if it is safe and can help improve movement.
CórdobaAges 18–65 - NCT06570603Recruiting
Study for people struggling with distress
This trial tests a program designed to help people who struggle with intense distress, anxiety, or depression. If you have a smartphone and find it hard to cope with emotional pain or stress, this study may teach you new skills to feel better.
Fayetteville, ArkansasAges 18 years+ - NCT06384352RecruitingPhase 1
Study of YL211 for advanced solid tumors
This trial tests a new drug, YL211, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for cancers like lung, colorectal, stomach, pancreatic, liver, bile duct, and head and neck cancers.
Aurora, ColoradoAges 18 years+
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 952 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.